rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
- 3 March 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 343 (1), 190-197
- https://doi.org/10.1016/j.bbrc.2006.02.141
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 33 references indexed in Scilit:
- Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic miceMolecular Therapy, 2005
- Increased expression of p62 in expanded polyglutamine‐expressing cells and its association with polyglutamine inclusionsJournal of Neurochemistry, 2004
- Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous SystemMolecular Therapy, 2004
- Identification of ubiquitin‐interacting proteins in purified polyglutamine aggregatesFEBS Letters, 2004
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disordersNature, 2003
- RNA Interference Gene Therapy: A story of mice and menGene Therapy, 2002
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Recombinant Adeno-associated Virus Serotypes 2– and 5–Mediated Gene Transfer in the Mammalian Brain: Quantitative Analysis of Heparin Co-infusionMolecular Therapy, 2002
- Impairment of the Ubiquitin-Proteasome System by Protein AggregationScience, 2001